1. Home
  2. ZYME vs CMRE Comparison

ZYME vs CMRE Comparison

Compare ZYME & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.43

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Costamare Inc. $0.0001 par value

CMRE

Costamare Inc. $0.0001 par value

HOLD

Current Price

$15.67

Market Cap

1.8B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
CMRE
Founded
2003
1974
Country
United States
Monaco
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
ZYME
CMRE
Price
$26.43
$15.67
Analyst Decision
Strong Buy
Hold
Analyst Count
9
1
Target Price
$32.75
$12.00
AVG Volume (30 Days)
589.6K
442.4K
Earning Date
11-06-2025
02-04-2026
Dividend Yield
N/A
2.91%
EPS Growth
N/A
N/A
EPS
N/A
2.51
Revenue
$134,481,000.00
$2,085,335,000.00
Revenue This Year
$63.57
N/A
Revenue Next Year
$89.45
N/A
P/E Ratio
N/A
$6.32
Revenue Growth
116.21
79.87
52 Week Low
$9.03
$6.63
52 Week High
$28.49
$16.40

Technical Indicators

Market Signals
Indicator
ZYME
CMRE
Relative Strength Index (RSI) 57.49 55.89
Support Level $26.10 $15.49
Resistance Level $26.91 $15.83
Average True Range (ATR) 0.95 0.34
MACD -0.25 -0.08
Stochastic Oscillator 49.84 59.80

Price Performance

Historical Comparison
ZYME
CMRE

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

Share on Social Networks: